Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna L Godfrey

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
The New England Journal of Medicine|February 12, 2015
Effect of mutation order on myeloproliferative neoplasmsChristina A Ortmann, David G Kent, Jyoti Nangalia, et al.
Blood|October 15, 2011
Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasmsLuca Malcovati, Elli Papaemmanuil, David T Bowen, et al.
Blood|November 14, 2023
Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinibAlex Rampotas, Luke Carter-Brzezinski, Tim C P Somervaille, et al.
The New England Journal of Medicine|October 11, 2018
Classification and Personalized Prognosis in Myeloproliferative NeoplasmsJacob Grinfeld, Jyoti Nangalia, E Joanna Baxter, et al.
Nature Communications|November 24, 2023
Tamoxifen for the treatment of myeloproliferative neoplasms: A Phase II clinical trial and exploratory analysisZijian Fang, Giuditta Corbizi Fattori, Thomas McKerrell, et al.
Leukemia|March 28, 2026
Myeloproliferative neoplasms with concomitant chronic myeloid leukemia are associated with TKI resistance and poor outcomesLaura Li Gagnon, Andrea Duminuco, Fabio Stagno, et al.
Nature Genetics|August 28, 2025
Telomere attrition becomes an instrument for clonal selection in aging hematopoiesis and leukemogenesisMatthew A McLoughlin, Sruthi Cheloor Kovilakam, William G Dunn, et al.
Nature Communications|April 8, 2015
Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasmsWilliam Tapper, Amy V Jones, Robert Kralovics, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
The New England Journal of Medicine|February 12, 2015
Effect of mutation order on myeloproliferative neoplasmsChristina A Ortmann, David G Kent, Jyoti Nangalia, et al.
Blood|October 15, 2011
Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasmsLuca Malcovati, Elli Papaemmanuil, David T Bowen, et al.
Blood|November 14, 2023
Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinibAlex Rampotas, Luke Carter-Brzezinski, Tim C P Somervaille, et al.
The New England Journal of Medicine|October 11, 2018
Classification and Personalized Prognosis in Myeloproliferative NeoplasmsJacob Grinfeld, Jyoti Nangalia, E Joanna Baxter, et al.
Nature Communications|November 24, 2023
Tamoxifen for the treatment of myeloproliferative neoplasms: A Phase II clinical trial and exploratory analysisZijian Fang, Giuditta Corbizi Fattori, Thomas McKerrell, et al.
Leukemia|March 28, 2026
Myeloproliferative neoplasms with concomitant chronic myeloid leukemia are associated with TKI resistance and poor outcomesLaura Li Gagnon, Andrea Duminuco, Fabio Stagno, et al.
Nature Genetics|August 28, 2025
Telomere attrition becomes an instrument for clonal selection in aging hematopoiesis and leukemogenesisMatthew A McLoughlin, Sruthi Cheloor Kovilakam, William G Dunn, et al.
Nature Communications|April 8, 2015
Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasmsWilliam Tapper, Amy V Jones, Robert Kralovics, et al.
Pageof 3